



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			☐ URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:					
F YOU ARE NOT THE PATIENT OR THE PRESCRI	GHT (IN/CM): WEIGH BER, YOU WILL NEED TO SUBMIT A PHI DISCLO M/MEMBER/EXTERNAL/COMMERCIAL/COMM	SURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE		
AUTHORIZED REPRESENTATIV	RESENTATIVE (IF APPLICABLE): /E'S PHONE NUMBER:				
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL	DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY RENEWAL IF RENEWAL: DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			Y INITIATED:		

Continued on next page.







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Pulmonary arterial hypertension (PAH□ Raynaud's phenomenon□ Diagnosis:		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A
Has patient tried and failed or has an a submit documentation.	absolute contraindication to generic silo	Jenafil suspension? □ Yes □ No Please
For <u>pulmonary arterial hypertension</u> , Does the patient have a diagnosis of documentation.	, answer the following: Group 1 pulmonary arterial hypertens	ion (PAH)? □ Yes □ No Please submit
Select if the diagnosis of Group 1 pulsetiologies:* Please submit documents Chronic hemolytic anemia	monary arterial hypertension (PAH) is o	caused by one of the follow ing
☐ Congenital heart disease (e.g., atria	ıl-septal defect)	
☐ Associated with surgical repair of a ventricular septal defect, patent duct	congenital systemic-to-pulmonary shu	unt of at least 1year in duration(e.g.,
☐ Drugs and toxins induced (not react	ive to acute vasoreactivity testing (AVT) or failed calcium channel blocker)CCB
treatment)		
 ☐ HIV infection ☐ Idiopathic/primary PAH ☐ Portal hypertension ☐ Schistosomiasis ☐ Tissue disease (e.g., lupus/SLE, RAsnodosa, mixed connective tissue disease *Please provide documentation. 	cleroderma, systemic sclerosis, CREST s ease)	syndrome, polymyositis, polyarteritis
Does the patient have WHO function *Please provide documentation.	al class II, III, or IV?* □ Yes □ No	
Is patient's diagnosis confirmed by ca	ardiac catheterization?	0
•	ed by cardiac catheterization a mean point a th to confirm PAH? \Box Yes \Box No *Pleas	

© 2017–2023 by Magellan Rx Management All Rights Reserved. Revision Date: 5/1/24 CAT0007







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Does patient have, (at rest), measured by cardiac catheterization a pulmonary capillary wedge pressure (PCWP) 15mmHg or less via right heart cath to confirm PAH? Yes No *Please provide documentation.
Does patient have, (at rest), measured by cardiac catheterization a pulmonary vascular resistance (PVR) value equaling 3 wood units or greater via right heart cath to confirm PAH? Yes No *Please provide documentation.
If patient has idiopathic PAH, hereditary PAH (excludes congenital heart disease like atrial=septal defect) or drug/toxin induced PAH, did patient have had an acute vasoreactivity test? Yes No *Please provide documentation.
Has patient been previously treated with a Calcium channel blocker? ☐ Yes ☐ No *Please provide documentation.
Select the prescribing physician's specialty: Cardiology Nephrology Pulmonology Rheumatology
Does patient have a history of left-sided heart disease? ☐ Yes ☐ No Please submit documentation.
Does patient have severe renal insufficiency? □ Yes □ No Please submit documentation.
Does patient have pulmonary hypertension related to conditions other than previously specified? ☐ Yes ☐ No
For Raynaud's phenomenon, answer the following:
Is the prescribing physician a rheumatologist? □ Yes □ No
Is the patient's Raynaud's phenomenon secondary to systemic sclerosis/scleroderma?* — Yes — No *Please provide documentation.
Has the patient received prior treatment with, and is intolerant of or resistant to, at least one calcium channel blocker?* Yes No *Please provide documentation.
Will the patient be using a calcium channel blocker on alternate days with Adcirca? ☐ Yes ☐ No
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

© 2017–2023 by Magellan Rx Management All Rights Reserved. Revision Date: 5/1/24 CAT0007

Page 3 of 4







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

© 2017–2023 by Magellan Rx Management All Rights Reserved. Revision Date: 5/1/24 CAT0007

